{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:30:03Z","timestamp":1773268203832,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04570-2","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:36:11Z","timestamp":1773210971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baxdrostat for the treatment of primary aldosteronism: current evidence"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3594-7061","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Menino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Goi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"10226","key":"4570_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","volume":"395","author":"S Yusuf","year":"2020","unstructured":"S. Yusuf, P. Joseph, S. Rangarajan et al., Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 395(10226), 795\u2013808 (2020). https:\/\/doi.org\/10.1016\/S0140-6736(19)32008-2","journal-title":"Lancet"},{"issue":"10258","key":"4570_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"C.J.L. Murray, A.Y. Aravkin, P. Zheng et al., Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 396(10258), 1223\u20131249 (2020). https:\/\/doi.org\/10.1016\/S0140-6736(20)30752-2","journal-title":"Lancet"},{"issue":"10","key":"4570_CR3","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/hyp.0000000000000249","volume":"82","author":"D.W. Jones","year":"2025","unstructured":"D.W. Jones, K.C. Ferdinand, S.J. Taler, AHA\/ACC\/AANP\/ et al., PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 82(10), e212\u2013e316 (2025). https:\/\/doi.org\/10.1161\/hyp.0000000000000249","journal-title":"Hypertension"},{"issue":"10304","key":"4570_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"B Zhou","year":"2021","unstructured":"B. Zhou, R.M. Carrillo-Larco, G. Danaei et al., Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 398(10304), 957\u2013980 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1","journal-title":"Lancet"},{"issue":"38","key":"4570_CR5","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"J.W. McEvoy, C.P. McCarthy, R.M. Bruno et al., 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European society of cardiology (ESC) and endorsed by the European society of endocrinology (ESE) and the European stroke organisation (ESO). Eur. Heart J. 45(38), 3912\u20134018 (2024). https:\/\/doi.org\/10.1093\/eurheartj\/ehae178","journal-title":"Eur. Heart J."},{"issue":"19","key":"4570_CR6","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/eurheartj\/eht534","volume":"35","author":"SF Rimoldi","year":"2013","unstructured":"S.F. Rimoldi, U. Scherrer, F.H. Messerli, Secondary arterial hypertension: when, who, and how to screen? Eur. Heart J. 35(19), 1245\u20131254 (2013). https:\/\/doi.org\/10.1093\/eurheartj\/eht534","journal-title":"Eur. Heart J."},{"issue":"1","key":"4570_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/m20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"J.M. Brown, M. Siddiqui, D.A. Calhoun et al., The unrecognized prevalence of primary aldosteronism: A Cross-sectional study. Ann. Intern. Med. 173(1), 10\u201320 (2020). https:\/\/doi.org\/10.7326\/m20-0065","journal-title":"Ann. Intern. Med."},{"issue":"10","key":"4570_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/hjh.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"P. Mulatero, S. Monticone, J. Deinum et al., Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J. Hypertens. 38(10), 1919\u20131928 (2020). https:\/\/doi.org\/10.1097\/hjh.0000000000002510","journal-title":"J. Hypertens."},{"issue":"14","key":"4570_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"S. Monticone, J. Burrello, D. Tizzani et al., Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69(14), 1811\u20131820 (2017). https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"4570_CR10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"G.P. Rossi, G. Bernini, C. Caliumi et al., A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48(11), 2293\u20132300 (2006). https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"4570_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12020-024-03751-1","volume":"85","author":"M Araujo-Castro","year":"2024","unstructured":"M. Araujo-Castro, J.G. Ruiz-S\u00e1nchez, P. Parra Ram\u00edrez et al., Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish societies involved in the management of primary aldosteronism. Endocrine. 85(1), 99\u2013121 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03751-1","journal-title":"Endocrine"},{"issue":"4","key":"4570_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cen.15296","volume":"103","author":"D Goyal","year":"2025","unstructured":"D. Goyal, M. Bhatt, T. Ghosh et al., Prevalence of primary aldosteronism among patients with hypertension. Clin. Endocrinol. (Oxf). 103(4), 447\u2013455 (2025). https:\/\/doi.org\/10.1111\/cen.15296","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"9628","key":"4570_CR13","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/s0140-6736(08)60834-x","volume":"371","author":"S Douma","year":"2008","unstructured":"S. Douma, K. Petidis, M. Doumas et al., Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 371(9628), 1921\u20131926 (2008). https:\/\/doi.org\/10.1016\/s0140-6736(08)60834-x","journal-title":"Lancet"},{"issue":"1","key":"4570_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"R.S. Vasan, J.C. Evans, M.G. Larson et al., Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl. J. Med. 351(1), 33\u201341 (2004). https:\/\/doi.org\/10.1056\/NEJMoa033263","journal-title":"N Engl. J. Med."},{"issue":"10","key":"4570_CR15","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1097\/hjh.0000000000000284","volume":"32","author":"L Petramala","year":"2014","unstructured":"L. Petramala, P. Pignatelli, R. Carnevale et al., Oxidative stress in patients affected by primary aldosteronism. J. Hypertens. 32(10), 2022\u20132029 (2014). discussion 9. https:\/\/doi.org\/10.1097\/hjh.0000000000000284","journal-title":"J. Hypertens."},{"issue":"1","key":"4570_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13098-025-01875-6","volume":"17","author":"Z Zhang","year":"2025","unstructured":"Z. Zhang, Y. Du, F. Zhang et al., Causal effects of primary aldosteronism on inflammation and bone density: evidence from Mendelian randomization, animal, and clinical studies. Diabetol. Metab. Syndr. 17(1), 303 (2025). https:\/\/doi.org\/10.1186\/s13098-025-01875-6","journal-title":"Diabetol. Metab. Syndr."},{"issue":"5","key":"4570_CR17","doi-asserted-by":"publisher","first-page":"e1967","DOI":"10.1210\/clinem\/dgz306","volume":"105","author":"CDCC van der Heijden","year":"2019","unstructured":"van der C.D.C.C. Heijden, E.M.M. Smeets, E.H.J.G. Aarntzen et al., Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism. J. Clin. Endocrinol. Metabolism. 105(5), e1967\u2013e80 (2019). https:\/\/doi.org\/10.1210\/clinem\/dgz306","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"12","key":"4570_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/jhh.2014.11","volume":"28","author":"G Liu","year":"2014","unstructured":"G. Liu, G.S. Yin, J.Y. Tang, D.J. Ma, J. Ru, X.H. Huang, Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage. J. Hum. Hypertens. 28(12), 711\u2013715 (2014). https:\/\/doi.org\/10.1038\/jhh.2014.11","journal-title":"J. Hum. Hypertens."},{"key":"4570_CR19","doi-asserted-by":"publisher","first-page":"1567876","DOI":"10.3389\/fendo.2025.1567876","volume":"16","author":"YL Chen","year":"2025","unstructured":"Y.L. Chen, C.H. Chen, X.F. Ye et al., Myocardial fibrosis in primary aldosteronism. Front. Endocrinol. (Lausanne). 16, 1567876 (2025). https:\/\/doi.org\/10.3389\/fendo.2025.1567876","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"4570_CR20","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"M. Stowasser, J. Sharman, R. Leano et al., Evidence for abnormal left ventricular structure and function in normotensive individuals with Familial hyperaldosteronism type I. J. Clin. Endocrinol. Metab. 90(9), 5070\u20135076 (2005). https:\/\/doi.org\/10.1210\/jc.2005-0681","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4570_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjhyper.2005.05.013","volume":"19","author":"K Matsumura","year":"2006","unstructured":"K. Matsumura, K. Fujii, H. Oniki, M. Oka, M. Iida, Role of aldosterone in left ventricular hypertrophy in hypertension. Am. J. Hypertens. 19(1), 13\u201318 (2006). https:\/\/doi.org\/10.1016\/j.amjhyper.2005.05.013","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"4570_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabet.2019.02.003","volume":"46","author":"C Bothou","year":"2020","unstructured":"C. Bothou, F. Beuschlein, A. Spyroglou, Links between aldosterone excess and metabolic complications: A comprehensive review. Diabetes Metab. 46(1), 1\u20137 (2020). https:\/\/doi.org\/10.1016\/j.diabet.2019.02.003","journal-title":"Diabetes Metab."},{"issue":"1","key":"4570_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti et al., Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6(1), 41\u201350 (2018). https:\/\/doi.org\/10.1016\/s2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4570_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/hjh.0000000000002216","volume":"38","author":"S Monticone","year":"2020","unstructured":"S. Monticone, E. Sconfienza, F. D\u2019Ascenzo et al., Renal damage in primary aldosteronism: a systematic review and meta-analysis. J. Hypertens. 38(1), 3\u201312 (2020). https:\/\/doi.org\/10.1097\/hjh.0000000000002216","journal-title":"J. Hypertens."},{"key":"4570_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.sleep.2023.12.007","volume":"114","author":"R Zhang","year":"2024","unstructured":"R. Zhang, X. Cai, C. Lin et al., Primary aldosteronism and obstructive sleep apnea: A meta-analysis of prevalence and metabolic characteristics. Sleep. Med. 114, 8\u201314 (2024). https:\/\/doi.org\/10.1016\/j.sleep.2023.12.007","journal-title":"Sleep. Med."},{"key":"4570_CR26","doi-asserted-by":"publisher","first-page":"870047","DOI":"10.3389\/fendo.2022.870047","volume":"13","author":"W Manosroi","year":"2022","unstructured":"W. Manosroi, P. Atthakomol, P. Wattanawitawas, S. Buranapin, Differences in glycemic abnormalities between primary aldosteronism and essential hypertension: A systematic review and Meta-Analysis. Front. Endocrinol. (Lausanne). 13, 870047 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.870047","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"4570_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/hypertensionaha.121.18118","volume":"79","author":"GL Hundemer","year":"2022","unstructured":"G.L. Hundemer, H. Imsirovic, A. Vaidya et al., Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A Population-Based retrospective cohort study. Hypertension. 79(1), 178\u2013186 (2022). https:\/\/doi.org\/10.1161\/hypertensionaha.121.18118","journal-title":"Hypertension"},{"issue":"11","key":"4570_CR28","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1097\/hjh.0000000000001088","volume":"34","author":"P Mulatero","year":"2016","unstructured":"P. Mulatero, S. Monticone, J. Burrello, F. Veglio, T.A. Williams, J. Funder, Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J. Hypertens. 34(11), 2253\u20132257 (2016). https:\/\/doi.org\/10.1097\/hjh.0000000000001088","journal-title":"J. Hypertens."},{"issue":"3","key":"4570_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.eprac.2021.11.085","volume":"28","author":"K Zekarias","year":"2022","unstructured":"K. Zekarias, K.M. Tessier, Screening rate for primary aldosteronism among patients with apparent Treatment-Resistant hypertension: retrospective analysis of current practice. Endocr. Pract. 28(3), 271\u2013275 (2022). https:\/\/doi.org\/10.1016\/j.eprac.2021.11.085","journal-title":"Endocr. Pract."},{"issue":"9","key":"4570_CR30","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"G.K. Adler, M. Stowasser, R.R. Correa et al., Primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 110(9), 2453\u20132495 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgaf284","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4570_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fendo.2020.00121","volume":"11","author":"Z Meng","year":"2020","unstructured":"Z. Meng, Z. Dai, K. Huang et al., Long-Term mortality for patients of primary aldosteronism compared with essential hypertension: A systematic review and Meta-Analysis. Front. Endocrinol. (Lausanne). 11, 121 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00121","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"4570_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6(1), 51\u201359 (2018). https:\/\/doi.org\/10.1016\/s2213-8587(17)30367-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"4570_CR33","doi-asserted-by":"publisher","first-page":"147032032110037","DOI":"10.1177\/14703203211003781","volume":"22","author":"Y Jing","year":"2021","unstructured":"Y. Jing, K. Liao, R. Li et al., Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis. J. Renin Angiotensin Aldosterone Syst. 22(1), 14703203211003781 (2021). https:\/\/doi.org\/10.1177\/14703203211003781","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"2","key":"4570_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/ejendo\/lvaf158","volume":"193","author":"J Goi","year":"2025","unstructured":"J. Goi, M. Paja Fano, A. Rizo Gellida et al., Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain. Eur. J. Endocrinol. 193(2), 297\u2013309 (2025). https:\/\/doi.org\/10.1093\/ejendo\/lvaf158","journal-title":"Eur. J. Endocrinol."},{"issue":"8","key":"4570_CR35","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1161\/hypertensionaha.125.25104","volume":"82","author":"L Marzano","year":"2025","unstructured":"L. Marzano, F. Zoccatelli, F. Pizzolo, S. Friso, Adrenalectomy versus medical therapy in primary aldosteronism: A Meta-Analysis of Long-Term cardiac remodeling and function: medical versus adrenalectomy treatment compared in hyperaldosteronism (MATCH) study. Hypertension. 82(8), e142\u2013e53 (2025). https:\/\/doi.org\/10.1161\/hypertensionaha.125.25104","journal-title":"Hypertension"},{"issue":"6","key":"4570_CR36","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1530\/eje-22-0375","volume":"187","author":"SY Chen","year":"2022","unstructured":"S.Y. Chen, J.Y. Chen, W.C. Huang et al., Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur. J. Endocrinol. 187(6), S47\u2013s58 (2022). https:\/\/doi.org\/10.1530\/eje-22-0375","journal-title":"Eur. J. Endocrinol."},{"key":"4570_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-med-042921-100438","volume":"74","author":"JB Cohen","year":"2023","unstructured":"J.B. Cohen, I. Bancos, J.M. Brown, H. Sarathy, A.F. Turcu, D.L. Cohen, Primary aldosteronism and the role of mineralocorticoid receptor antagonists for the heart and kidneys. Annu. Rev. Med. 74, 217\u2013230 (2023). https:\/\/doi.org\/10.1146\/annurev-med-042921-100438","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"4570_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s2213-8587(24)00308-5","volume":"13","author":"J Yang","year":"2025","unstructured":"J. Yang, J. Burrello, J. Goi et al., Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diabetes Endocrinol. 13(2), 119\u2013133 (2025). https:\/\/doi.org\/10.1016\/s2213-8587(24)00308-5","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"4570_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"M.W. Freeman, Y.D. Halvorsen, W. Marshall et al., Phase 2 trial of Baxdrostat for Treatment-Resistant hypertension. N Engl. J. Med. 388(5), 395\u2013405 (2023). https:\/\/doi.org\/10.1056\/NEJMoa2213169","journal-title":"N Engl. J. Med."},{"issue":"14","key":"4570_CR40","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"J.M. Flack, M. Azizi, J.M. Brown et al., Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension. N Engl. J. Med. 393(14), 1363\u20131374 (2025). https:\/\/doi.org\/10.1056\/NEJMoa2507109","journal-title":"N Engl. J. Med."},{"key":"4570_CR41","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000849","author":"JP Dwyer","year":"2025","unstructured":"J.P. Dwyer, N. Maklad, O. Vedin et al., Efficacy and safety of Baxdrostat in participants with CKD and uncontrolled hypertension: A Randomized, Double-Blind, Placebo-Controlled trial. J. Am. Soc. Nephrol. (2025). https:\/\/doi.org\/10.1681\/ASN.0000000849","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"4570_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"A.F. Turcu, M.W. Freeman, I. Bancos et al., Phase 2a study of Baxdrostat in primary aldosteronism. N Engl. J. Med. 393(5), 515\u2013518 (2025). https:\/\/doi.org\/10.1056\/NEJMc2508629","journal-title":"N Engl. J. Med."},{"issue":"1","key":"4570_CR43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","volume":"106","author":"TA Williams","year":"2021","unstructured":"T.A. Williams, C.E. Gomez-Sanchez, W.E. Rainey et al., International histopathology consensus for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 106(1), 42\u201354 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa484","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4570_CR44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1152\/physrev.00011.2014","volume":"95","author":"BC Rossier","year":"2015","unstructured":"B.C. Rossier, M.E. Baker, R.A. Studer, Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol. Rev. 95(1), 297\u2013340 (2015). https:\/\/doi.org\/10.1152\/physrev.00011.2014","journal-title":"Physiol. Rev."},{"issue":"4","key":"4570_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","volume":"75","author":"J Burrello","year":"2020","unstructured":"J. Burrello, S. Monticone, I. Losano et al., Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension. 75(4), 1025\u20131033 (2020). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14063","journal-title":"Hypertension"},{"issue":"16","key":"4570_CR46","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.2174\/1389450119666180326125926","volume":"19","author":"P Kolodziejczyk","year":"2018","unstructured":"P. Kolodziejczyk, A. Gromotowicz-Poplawska, M. Aleksiejczuk, E. Chabielska, P. Tutka, W. Miltyk, New sides of aldosterone action in cardiovascular system as potential targets for therapeutic intervention. Curr. Drug Targets. 19(16), 1968\u20131979 (2018). https:\/\/doi.org\/10.2174\/1389450119666180326125926","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"4570_CR47","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1210\/me.2004-0469","volume":"19","author":"C Grossmann","year":"2005","unstructured":"C. Grossmann, A. Benesic, A.W. Krug et al., Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol. Endocrinol. 19(7), 1697\u20131710 (2005). https:\/\/doi.org\/10.1210\/me.2004-0469","journal-title":"Mol. Endocrinol."},{"issue":"1\u20132","key":"4570_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","volume":"308","author":"C Grossmann","year":"2009","unstructured":"C. Grossmann, M. Gekle, New aspects of rapid aldosterone signaling. Mol. Cell. Endocrinol. 308(1\u20132), 53\u201362 (2009). https:\/\/doi.org\/10.1016\/j.mce.2009.02.005","journal-title":"Mol. Cell. Endocrinol."},{"issue":"8","key":"4570_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"N.J. Brown, Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol. 9(8), 459\u2013469 (2013). https:\/\/doi.org\/10.1038\/nrneph.2013.110","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"4570_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","volume":"86","author":"F Fioretti","year":"2025","unstructured":"F. Fioretti, J.M. Testani, M.C. Tio, B. Pitt, J. Butler, Aldosterone and aldosterone modulation in Cardio-Kidney diseases. J. Am. Coll. Cardiol. 86(5), 354\u2013373 (2025). https:\/\/doi.org\/10.1016\/j.jacc.2025.06.012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"4570_CR51","doi-asserted-by":"publisher","first-page":"H1067","DOI":"10.1152\/ajpheart.01131.2007","volume":"294","author":"ZH Zhang","year":"2008","unstructured":"Z.H. Zhang, Y. Yu, Y.M. Kang, S.G. Wei, R.B. Felder, Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am. J. Physiol. Heart Circ. Physiol. 294(2), H1067\u2013H1074 (2008). https:\/\/doi.org\/10.1152\/ajpheart.01131.2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"4570_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bbrc.2004.04.026","volume":"318","author":"K Rossol-Haseroth","year":"2004","unstructured":"K. Rossol-Haseroth, Q. Zhou, S. Braun et al., Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem. Biophys. Res. Commun. 318(1), 281\u2013288 (2004). https:\/\/doi.org\/10.1016\/j.bbrc.2004.04.026","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"4570_CR53","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1210\/me.2014-1410","volume":"29","author":"AW Ashton","year":"2015","unstructured":"A.W. Ashton, T.Y. Le, C.E. Gomez-Sanchez et al., Role of nongenomic signaling pathways activated by aldosterone during cardiac reperfusion injury. Mol. Endocrinol. 29(8), 1144\u20131155 (2015). https:\/\/doi.org\/10.1210\/me.2014-1410","journal-title":"Mol. Endocrinol."},{"issue":"9","key":"4570_CR54","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1097\/01.asn.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"S. Arima, K. Kohagura, H.L. Xu et al., Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14(9), 2255\u20132263 (2003). https:\/\/doi.org\/10.1097\/01.asn.0000083982.74108.54","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"4570_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1291\/hypres.31.363","volume":"31","author":"H Hayashi","year":"2008","unstructured":"H. Hayashi, M. Kobara, M. Abe et al., Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens. Res. 31(2), 363\u2013375 (2008). https:\/\/doi.org\/10.1291\/hypres.31.363","journal-title":"Hypertens. Res."},{"issue":"2","key":"4570_CR56","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.freeradbiomed.2012.05.011","volume":"53","author":"N Queisser","year":"2012","unstructured":"N. Queisser, N. Schupp, Aldosterone, oxidative stress, and NF-\u03baB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol. Med. 53(2), 314\u2013327 (2012). https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.05.011","journal-title":"Free Radic Biol. Med."},{"issue":"12","key":"4570_CR57","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1210\/mend-5-12-1853","volume":"5","author":"LJ Domalik","year":"1991","unstructured":"L.J. Domalik, D.D. Chaplin, M.S. Kirkman et al., Different isozymes of mouse 11 beta-hydroxylase produce mineralocorticoids and glucocorticoids. Mol. Endocrinol. 5(12), 1853\u20131861 (1991). https:\/\/doi.org\/10.1210\/mend-5-12-1853","journal-title":"Mol. Endocrinol."},{"issue":"17","key":"4570_CR58","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1073\/pnas.89.17.8327","volume":"89","author":"L Pascoe","year":"1992","unstructured":"L. Pascoe, K.M. Curnow, L. Slutsker et al., Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc. Natl. Acad. Sci. U S A 89(17), 8327\u20138331 (1992). https:\/\/doi.org\/10.1073\/pnas.89.17.8327","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1\u20132","key":"4570_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2014.05.002","volume":"392","author":"Y Nakamura","year":"2014","unstructured":"Y. Nakamura, T. Maekawa, S.J. Felizola et al., Adrenal CYP11B1\/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies. Mol. Cell. Endocrinol. 392(1\u20132), 73\u201379 (2014). https:\/\/doi.org\/10.1016\/j.mce.2014.05.002","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"4570_CR60","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/hypertensionaha.121.16498","volume":"79","author":"UI Scholl","year":"2022","unstructured":"U.I. Scholl, Genetics of primary aldosteronism. Hypertension. 79(5), 887\u2013897 (2022). https:\/\/doi.org\/10.1161\/hypertensionaha.121.16498","journal-title":"Hypertension"},{"issue":"4","key":"4570_CR61","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/07435809609043735","volume":"22","author":"CD Clyne","year":"1996","unstructured":"C.D. Clyne, P.C. White, W.E. Rainey, Calcium regulates human CYP11B2 transcription. Endocr. Res. 22(4), 485\u2013492 (1996). https:\/\/doi.org\/10.1080\/07435809609043735","journal-title":"Endocr. Res."},{"issue":"6357","key":"4570_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"R.P. Lifton, R.G. Dluhy, M. Powers et al., A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 355(6357), 262\u2013265 (1992). https:\/\/doi.org\/10.1038\/355262a0","journal-title":"Nature"},{"issue":"9","key":"4570_CR63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/s2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"T.A. Williams, J.W.M. Lenders, P. Mulatero et al., Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 5(9), 689\u2013699 (2017). https:\/\/doi.org\/10.1016\/s2213-8587(17)30135-3","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"4570_CR64","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12020-024-03773-9","volume":"85","author":"M Araujo-Castro","year":"2024","unstructured":"M. Araujo-Castro, J.G. Ruiz-S\u00e1nchez, P.P. Ram\u00edrez et al., Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document. Endocrine. 85(2), 532\u2013544 (2024). https:\/\/doi.org\/10.1007\/s12020-024-03773-9","journal-title":"Endocrine"},{"issue":"46","key":"4570_CR65","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.2174\/1381612825666190311130138","volume":"24","author":"K Stavropoulos","year":"2018","unstructured":"K. Stavropoulos, C. Papadopoulos, K. Koutsampasopoulos, G. Lales, C. Mitas, M. Doumas, Mineralocorticoid receptor antagonists in primary aldosteronism. Curr. Pharm. Des. 24(46), 5508\u20135516 (2018). https:\/\/doi.org\/10.2174\/1381612825666190311130138","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"4570_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"B. Pitt, F. Zannad, W.J. Remme et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl. J. Med. 341(10), 709\u2013717 (1999). https:\/\/doi.org\/10.1056\/nejm199909023411001","journal-title":"N Engl. J. Med."},{"issue":"14","key":"4570_CR67","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"B. Pitt, W. Remme, F. Zannad et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl. J. Med. 348(14), 1309\u20131321 (2003). https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl. J. Med."},{"issue":"10458","key":"4570_CR68","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"P.S. Jhund, A. Talebi, A.D. Henderson et al., Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 404(10458), 1119\u20131131 (2024). https:\/\/doi.org\/10.1016\/s0140-6736(24)01733-1","journal-title":"Lancet"},{"issue":"6","key":"4570_CR69","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.cir.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"C.A. Farquharson, A.D. Struthers, Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation. 101(6), 594\u2013597 (2000). https:\/\/doi.org\/10.1161\/01.cir.101.6.594","journal-title":"Circulation"},{"issue":"4","key":"4570_CR70","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/01.hyp.0000034738.79310.06","volume":"40","author":"A Virdis","year":"2002","unstructured":"A. Virdis, M.F. Neves, F. Amiri, E. Viel, R.M. Touyz, E.L. Schiffrin, Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 40(4), 504\u2013510 (2002). https:\/\/doi.org\/10.1161\/01.hyp.0000034738.79310.06","journal-title":"Hypertension"},{"key":"4570_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"P Kolkhof","year":"2017","unstructured":"P. Kolkhof, F. Jaisser, S.Y. Kim, G. Filippatos, C. Nowack, B. Pitt, Steroidal and novel Non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb. Exp. Pharmacol. 243, 271\u2013305 (2017). https:\/\/doi.org\/10.1007\/164_2016_76","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5","key":"4570_CR72","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"H.K. Parthasarathy, J. M\u00e9nard, W.B. White et al., A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 29(5), 980\u2013990 (2011). https:\/\/doi.org\/10.1097\/HJH.0b013e3283455ca5","journal-title":"J. Hypertens."},{"key":"4570_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"M. Lainscak, F. Pelliccia, G. Rosano et al., Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int. J. Cardiol. 200, 25\u201329 (2015). https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.127","journal-title":"Int. J. Cardiol."},{"issue":"1\u20132","key":"4570_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"S.M. Garthwaite, E.G. McMahon, The evolution of aldosterone antagonists. Mol. Cell. Endocrinol. 217(1\u20132), 27\u201331 (2004). https:\/\/doi.org\/10.1016\/j.mce.2003.10.005","journal-title":"Mol. Cell. Endocrinol."},{"issue":"20","key":"4570_CR75","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1021\/acs.jmedchem.5b00851","volume":"58","author":"RE Martin","year":"2015","unstructured":"R.E. Martin, J.D. Aebi, B. Hornsperger et al., Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and orally active aldosterone synthase (CYP11B2) inhibitors: in vivo evaluation in rodents and cynomolgus monkeys. J. Med. Chem. 58(20), 8054\u20138065 (2015). https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00851","journal-title":"J. Med. Chem."},{"issue":"1","key":"4570_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/hypertensionaha.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"K. Bogman, D. Schwab, M.L. Delporte et al., Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 69(1), 189\u2013196 (2017). https:\/\/doi.org\/10.1161\/hypertensionaha.116.07716","journal-title":"Hypertension"},{"issue":"1","key":"4570_CR77","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"M.W. Freeman, M. Bond, B. Murphy, J. Hui, J. Isaacsohn, Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor Baxdrostat in healthy volunteers. Hypertens. Res. 46(1), 108\u2013118 (2023). https:\/\/doi.org\/10.1038\/s41440-022-01070-4","journal-title":"Hypertens. Res."},{"issue":"12","key":"4570_CR78","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2174\/1568026611313120003","volume":"13","author":"MA Cerny","year":"2013","unstructured":"M.A. Cerny, Progress towards clinically useful aldosterone synthase inhibitors. Curr. Top. Med. Chem. 13(12), 1385\u20131401 (2013). https:\/\/doi.org\/10.2174\/1568026611313120003","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"4570_CR79","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","volume":"13","author":"MW Freeman","year":"2024","unstructured":"M.W. Freeman, Y.D. Halvorsen, M. Bond, B. Murphy, J. Isaacsohn, Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor Baxdrostat in participants with varying degrees of renal function. Clin. Pharmacol. Drug Dev. 13(4), 410\u2013418 (2024). https:\/\/doi.org\/10.1002\/cpdd.1371","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"11","key":"4570_CR80","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s40265-025-02229-2","volume":"85","author":"AFG Cicero","year":"2025","unstructured":"A.F.G. Cicero, G. Tocci, A. Avagimyan et al., Aldosterone synthase inhibitors for resistant hypertension: Pharmacological Insights - A systematic review. Drugs. 85(11), 1429\u20131453 (2025). https:\/\/doi.org\/10.1007\/s40265-025-02229-2","journal-title":"Drugs"},{"key":"4570_CR81","unstructured":"ClinicalTrials.gov, A Study of CIN-107 in Patients With Uncontrolled Hypertension (HALO). https:\/\/clinicaltrials.gov\/study\/NCT05137002 (2023). Accessed 09 November 2025"},{"issue":"11","key":"4570_CR82","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1038\/s41440-025-02297-7","volume":"48","author":"JM Flack","year":"2025","unstructured":"J.M. Flack, M. Azizi, J.M. Brown et al., Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens. Res. 48(11), 2911\u20132923 (2025). https:\/\/doi.org\/10.1038\/s41440-025-02297-7","journal-title":"Hypertens. Res."},{"key":"4570_CR83","unstructured":"ClinicalTrials.gov, A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (Bax24). https:\/\/clinicaltrials.gov\/study\/NCT06168409 (2024). Accessed 10 November 2025"},{"key":"4570_CR84","unstructured":"AstraZeneca, Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmhg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/bax24-phase-iii-trial-full-results.html (2025). Accessed 17th of January 2026."},{"key":"4570_CR85","unstructured":"ClinicalTrials.gov, A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxAsia). https:\/\/www.clinicaltrials.gov\/study\/NCT06168409 (2024). Accessed 10 November 2025"},{"key":"4570_CR86","unstructured":"ClinicalTrials.gov, A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism (BaxPA). https:\/\/clinicaltrials.gov\/study\/NCT07007793 (2025). Accessed 11 November 2025"},{"key":"4570_CR87","unstructured":"ClinicalTrials.gov, A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. https:\/\/clinicaltrials.gov\/study\/NCT06268873 (2024). Accessed 10 November 2025"},{"key":"4570_CR88","unstructured":"ClinicalTrials.gov, A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific). https:\/\/clinicaltrials.gov\/study\/NCT06742723 (2025). Accessed 10 November 2025"},{"key":"4570_CR89","unstructured":"ClinicalTrials.gov, Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (Prevent-HF). https:\/\/clinicaltrials.gov\/study\/NCT06677060 (2025). Accessed 10 November 2025"},{"issue":"9","key":"4570_CR90","doi-asserted-by":"publisher","first-page":"e70155","DOI":"10.1111\/jch.70155","volume":"27","author":"A Dad","year":"2025","unstructured":"A. Dad, K. Bakht, H.B. Tahir et al., Efficacy and safety of Lorundrostat in uncontrolled hypertension: A systematic review and Meta-Analysis. J. Clin. Hypertens. (Greenwich). 27(9), e70155 (2025). https:\/\/doi.org\/10.1111\/jch.70155","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"4570_CR91","doi-asserted-by":"publisher","unstructured":"P. Mulatero, G. Wuerzner, M. Groessl et al., Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. eClinicalMedicine. 71 (2024). https:\/\/doi.org\/10.1016\/j.eclinm.2024.102576","DOI":"10.1016\/j.eclinm.2024.102576"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04570-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04570-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04570-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:36:13Z","timestamp":1773210973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04570-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4570"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04570-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"113"}}